age – Medxy AI

Bariatric Surgery and Risk of Obesity-Related Cancer by Age and Sex: A Comprehensive Review

By MedXY 10/19/2026

This review synthesizes evidence from large cohort studies and meta-analyses highlighting bariatric surgery's association with reduced risks of many obesity-related cancers, consistent across age and sex. Mechanistic insights and implications for equitable surgical access are discussed.

General Surgery news

Beyond Age: Frailty as a Superior Predictor of Postoperative Outcomes in Older Adults

By MedXY 10/06/2026

A 2022 national study shows frailty, not chronological age, is a stronger predictor of 30-day postoperative mortality across surgical risk levels, challenging age-based surgical decision-making.

Clinical Updates Hematology-Oncology news

Age, Anthracycline Use, and Mortality Outcomes in Classic Hodgkin Lymphoma: Insights from a Large Complete Population Cohort

By MedXY 09/20/2026

This review analyzes the impact of age and anthracycline-based chemotherapy on mortality in 28,000 classic Hodgkin lymphoma patients, highlighting poorer outcomes in the elderly and the therapeutic nuances influencing survival.

Neurology news Otorhinolaryngology

Synergistic Impact of Age and Nerve Degeneration on Bell’s Palsy Recovery: Clinical Implications

By MedXY 09/14/2026

Older adults with severe nerve impairment in Bell's palsy experience markedly poorer recovery, highlighting the critical role of early, aggressive intervention.

news Oncology Otorhinolaryngology

TERT Promoter Variants and Age: Refining Prognostic Precision in Papillary Thyroid Carcinoma

By MedXY 08/23/2026

This analysis reveals that TERT promoter mutations, increasingly prevalent with age, better predict poor outcomes in papillary thyroid carcinoma than age alone, offering enhanced risk stratification for clinical management.

Neurology news Oncology

Reevaluating Age as a Prognostic Marker in Molecularly Defined Lower-Grade Gliomas

By MedXY 08/13/2026

This article examines how age, traditionally considered a high-risk factor in lower-grade gliomas, influences prognosis and treatment decisions in the molecular era, highlighting the importance of IDH mutation status.

news Oncology Urology

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY 10/30/2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains from intensified therapy.